Last reviewed · How we verify
Lercanidipine/enalapril fixed combination
This fixed combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (lercanidipine) and inhibiting angiotensin-converting enzyme (enalapril).
This fixed combination reduces blood pressure by blocking calcium channels in vascular smooth muscle (lercanidipine) and inhibiting angiotensin-converting enzyme (enalapril). Used for Hypertension.
At a glance
| Generic name | Lercanidipine/enalapril fixed combination |
|---|---|
| Also known as | Vasodip Combo 20, hypertension, ambulatory blood pressure monitoring |
| Sponsor | Meir Medical Center |
| Drug class | Calcium channel blocker / ACE inhibitor combination |
| Target | L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Lercanidipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation. Enalapril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Together, these complementary mechanisms provide synergistic antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Headache
- Dizziness
- Peripheral edema
- Cough
- Fatigue
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: